logo-loader

Redx Pharma agrees research collaboration with one of Australia's leading medical research centres

Published: 02:53 05 Apr 2022 EDT

Redx Pharma PLC -

Redx Pharma PLC (AIM:REDX) has teamed up with one of Australia’s leading medical research centres to better understand how to tackle very poorly treated highly fibrotic cancers, including pancreatic cancer.

Scientists at the Garvan Institute of Medical Research will use patient-derived preclinical models to assess the impact of Redx molecules.

The first data from the tie-up is expected to be presented at an industry conference in June with more information on the research shared later this year.

Redx said the new insights will enhance the understanding of Wnt-ligand driven tumours, the target patient group for RXC004, its phase II drug, which is being used to treat people with pancreatic, colorectal and biliary cancers.

"We are thrilled to be combining the Garvan's world-leading research in our key areas of focus, fibrotic cancers and cancer-associated fibrosis, to explore the potential of Redx's molecules and novel targets in this leading collaboration,” said Dr Caroline Phillips, Redx’s head of oncology.

“With our focus on fibrosis and oncology and our world-class medicinal chemistry, we are able to contribute a range of molecules from Redx's differentiated pipeline to further research and develop new targeted therapies for these hard-to-treat conditions."

Novo Resources sees substantial upside potential at Nunyerry

Novo Resources Corp (TSX:NVO, OTCQX:NSRPF, ASX:NVO) co-chair and acting CEO Mike Spreadborough joins Jonathan Jackson in the Proactive studio to discuss promising gold outcomes from recent reanalysis of drill intercepts in a 2023 program at Nunyerry North in Western Australia. Using advanced...

8 hours, 20 minutes ago